Physician profile
Michael L Dunn
NPI 1922155688
$1,978.91
in general payments reported to CMS, 2019-2025
28 companies · $63.46 in 2025
The $63.46 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $236 · 2021: $509 · 2022: $194 · 2023: $224 · 2024: $301 · 2025: $63.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $451.57 | 2019-2023 | Veozah |
| Axonics, INC. | $263.18 | 2022-2024 | Bulkamid, Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.95 | 2019-2025 | Xifaxan |
| Pfizer INC. | $178.15 | 2019-2022 | |
| Allergan, INC. | $127.28 | 2019-2020 | |
| Medtronic, INC. | $124.49 | 2023 | Interstim, Nuro |
| Janssen Pharmaceuticals, INC | $82.38 | 2019 | |
| Abbvie INC. | $66.94 | 2019-2023 | Botox |
| Eisai INC. | $53.20 | 2020-2022 | |
| Medtronic USA, INC. | $45.63 | 2020 | |
| Merck Sharp & Dohme LLC | $36.63 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Circassia INC. | $35.27 | 2019 | |
| Therapeuticsmd, INC. | $32.66 | 2019 | |
| Exact Sciences Corporation | $29.50 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $28.81 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $28.37 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.38 | 2022 | |
| Hikma Pharmaceuticals USA | $21.32 | 2020 | |
| Glaxosmithkline, LLC. | $20.48 | 2024 | Arexvy |
| Novo Nordisk INC | $18.22 | 2024 | Wegovy |
| Ibsa Pharma INC. | $17.92 | 2019 | |
| Sanofi Pasteur INC. | $17.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.50 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.46 | 2019 | |
| Currax Pharmaceuticals LLC | $13.08 | 2022 | |
| Hologic Sales and Service, LLC | $10.75 | 2019 | |
| Organon LLC | $8.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.